Thyroid cancer is the most common endocrine tumor. Four targeted agents (vandetanib, cabozantinib, sorafenib, and lenvatinib) have attained regulatory approval for advanced thyroid cancer, and several other related agents are now commonly used off-label as first- and second-line treatments for selected patients.
This report contains market size and forecasts of Medicine for the Treatment of Advanced Thyroid Cancer in global, including the following market information:
Global Medicine for the Treatment of Advanced Thyroid Cancer Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Medicine for the Treatment of Advanced Thyroid Cancer Market Sales, 2017-2022, 2023-2028, (Tons)
Global top five Medicine for the Treatment of Advanced Thyroid Cancer companies in 2021 (%)
The global Medicine for the Treatment of Advanced Thyroid Cancer market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Cabozantinib Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Medicine for the Treatment of Advanced Thyroid Cancer include Bayer, AstraZeneca, Sanofi, Exelixis Inc., Ipsen Pharma and Eisai Inc, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Medicine for the Treatment of Advanced Thyroid Cancer manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Medicine for the Treatment of Advanced Thyroid Cancer Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (Tons)
Global Medicine for the Treatment of Advanced Thyroid Cancer Market Segment Percentages, by Type, 2021 (%)
Cabozantinib
Sorafenib
Vandetanib
Lenvatinib
Global Medicine for the Treatment of Advanced Thyroid Cancer Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (Tons)
Global Medicine for the Treatment of Advanced Thyroid Cancer Market Segment Percentages, by Application, 2021 (%)
Combination therapy
Solo Medication
Global Medicine for the Treatment of Advanced Thyroid Cancer Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (Tons)
Global Medicine for the Treatment of Advanced Thyroid Cancer Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Medicine for the Treatment of Advanced Thyroid Cancer revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Medicine for the Treatment of Advanced Thyroid Cancer revenues share in global market, 2021 (%)
Key companies Medicine for the Treatment of Advanced Thyroid Cancer sales in global market, 2017-2022 (Estimated), (Tons)
Key companies Medicine for the Treatment of Advanced Thyroid Cancer sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Bayer
AstraZeneca
Sanofi
Exelixis Inc.
Ipsen Pharma
Eisai Inc